A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra)
This BIM demonstrates that uptake of subcutaneous IgPro20 PFS is expected to be associated with substantial savings for a US IDN, including drug cost savings if offset by reduced non-PFS SCIG-packaging use.
Authors
- Rashad Carlton
- Rajiv Mallick (ORCID: https://orcid.org/0000-0002-0273-9680)
Institutions
- CSL (United States) (US)
- Macula Vision Research Foundation (US)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1007/s41669-025-00594-y
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00